HSIC vs JNJ

HSIC exhibits strong fundamental health with a Piotroski F-Score of 7/9, indicating robust operational efficiency and financial stability. While the current price of $75.34 is well above the defensive Graham Number ($45.41), it trades at a discount to its growth-based intrinsic value of $89.60 and the analyst target of $89.23. The company shows positive YoY revenue and earnings growth, though thin profit margins and bearish insider sentiment provide a cautionary counterweight. Overall, the valuation appears attractive on a forward P/E basis (12.82) relative to its historical stability.

JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.